NLRP3 and metabolic dysfunction-associated steatohepatitis: MCC950, an inhibitor of NLRP3, reduces the degree of fibrosis in methionine/choline-deficient (MCD)-induced non-alcoholic steatohepatitis (NASH) in mice [55].